Shopping Cart 0
Cart Subtotal
USD 0

KOL Perspectives: Biomarker Potential of Type I IFN Gene Signature in Lupus

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

KOL Perspectives: Biomarker Potential of Type I IFN Gene Signature in Lupus

Summary

This KOL Insight briefing focuses on the IFN gene signature as a potential biomarker in Lupus.

The briefing includes analysis of KOL opinion on the following topic areas-

- Awareness of biomarkers and predictors of disease activity in lupus

- Usefulness of the type I IFN signature test to identify patients who are most likely to respond to IFN-targeting therapies

- Impact of availability of a biomarker on willingness to prescribe a therapy

- Implementing a potential IFN biomarker test in clinical practice

- Willingness to prescribe anifrolumab to patients who do not display the interferon biomarker

- Barriers to using IFN signature test to stratify patients in clinical practice

- Impact of data suggesting that high IFN? gene expression is closely associated with SLE on opinion of anifrolumab's efficacy

- Impact of data suggesting that high IFN? gene expression is more closely associated with LN than IFN? on opinion of anifrolumab's efficacy

Key Highlights

- Majority of KOLs use complement & anti-DNA to monitor disease activity in clinical practice, while most are aware of the type I IFN signature test

- Most KOLs flagged that the type I IFN signature test will be useful to stratify patients most likely to respond to type I IFN-targeting therapies

- Most KOLs agreed that the availability of a biomarker would strongly influence their willingness to prescribe a therapy such as anifrolumab.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders (KOLs)

- In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based

- Interviews performed in December 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Biomarker Potential of Type I IFN Gene Signature in Lupus"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

IFN, lupus, anifrolumab, interferon


Companies

AstraZeneca

KOL Perspectives: Biomarker Potential of Type I IFN Gene Signature in Lupus

Summary

This KOL Insight briefing focuses on the IFN gene signature as a potential biomarker in Lupus.

The briefing includes analysis of KOL opinion on the following topic areas-

- Awareness of biomarkers and predictors of disease activity in lupus

- Usefulness of the type I IFN signature test to identify patients who are most likely to respond to IFN-targeting therapies

- Impact of availability of a biomarker on willingness to prescribe a therapy

- Implementing a potential IFN biomarker test in clinical practice

- Willingness to prescribe anifrolumab to patients who do not display the interferon biomarker

- Barriers to using IFN signature test to stratify patients in clinical practice

- Impact of data suggesting that high IFN? gene expression is closely associated with SLE on opinion of anifrolumab's efficacy

- Impact of data suggesting that high IFN? gene expression is more closely associated with LN than IFN? on opinion of anifrolumab's efficacy

Key Highlights

- Majority of KOLs use complement & anti-DNA to monitor disease activity in clinical practice, while most are aware of the type I IFN signature test

- Most KOLs flagged that the type I IFN signature test will be useful to stratify patients most likely to respond to type I IFN-targeting therapies

- Most KOLs agreed that the availability of a biomarker would strongly influence their willingness to prescribe a therapy such as anifrolumab.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders (KOLs)

- In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based

- Interviews performed in December 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Biomarker Potential of Type I IFN Gene Signature in Lupus"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

IFN, lupus, anifrolumab, interferon


Companies

AstraZeneca